Answers are grounded in this paper and cite their sources.
Editorial on the Research TopicOvercoming drug relapse and therapy resistance in NSCLC Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a 5year survival rate of less than 25% (1).Current treatment modalities include surgery, radiotherapy, and chemotherapy; however, most individuals are diagnosed at a locally advanced or metastatic stage when curative treatments are unavailable (2).Despite the success of targeted therapies and immunotherapies, drug resistance continues to be a major challenge in the management of NSCLC.Tumor cells can develop drug resistance through several mechanisms, including the acquisition of genetic mutations, aberrant activation of signaling pathways, alterations in the tumor microenvironment, and selection for drugresistant subpopulations (3).As a result, patients often experience disease progression and relapse after initial response to therapy.In some cases, complete responders with minimal to no detectable disease post-treatment eventually develop drug resistance and succumb to tumor progression.This Research Topic focuses on the latest research findings and insights into the immunological and molecular mechanisms that underpin NSCLC drug relapse and therapy resistance.The articles in this Research Topic cover a range of topics, including the identification of novel biomarkers to predict resistance, tumor heterogeneity in metastatic disease, metabolic vulnerabilities, and the design of new strategies to improve treatment outcomes.Together, they provide a comprehensive overview of the current state of research into NSCLC drug resistance, and highlight promising new directions for future studies.Accurate assessment of the tumor microenvironment is essential to understanding mechanisms of treatment resistance.Reviewed in this Research Topic, Rangamuwa et al. describe "immune phenotyping" which characterizes the immune milieu of the tumor, and may provide insights into response to immune-modulating therapy.A range of techniques may be employed to examine the tumor microenvironment, including immunohistochemistry, Frontiers in Oncology frontiersin.
No takes yet. Share an insight, caveat, or question.
Parakh et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: